Models are in therapeutic areas that include neuroscience, diabetes, and cardiovascular disease.
Charles River Laboratories inked an agreement with Pfizer to market and distribute to researchers worldwide precompetitive, transgenic research models. The Pfizer-developed models are in therapeutic areas that include neuroscience, diabetes, and cardiovascular disease.
The models will be used in research to target specific disease states and genetic markers, says Dr. Iva Morse, corporate vp, global research model services at Charles River.
Rick Connell, Pfizer’s vp and worldwide head of external research solutions center of excellence, says the agreement “aligns with Pfizer’s strategy to externalize our precompetitive tools and assets to a broader community of scientists outside of Pfizer’s walls.”